Zaltrap intravitreal (ziv-aflibercept intravitreal) / Regeneron, Sanofi - LARVOL DELTA

Intravitreal ziv-aflibercept for myopic macular neovascularization after pars plana vitrectomy and silicone oil tamponade: a case report. (PubMed, Ann Med Surg (Lond)) - "This case highlights its potential to achieve mMNV regression and improve visual acuity, thereby preventing irreversible vision loss in affected individuals. Further studies are warranted to establish standardized protocols for its use in similar clinical scenarios."

Journal • Ophthalmology

Anti-vascular endothelial growth factor therapies in ophthalmology. (PubMed, Med Hypothesis Discov Innov Ophthalmol) - "Keywords used in the search strategy included terms such as "anti-VEGF therapy", "biosimilar pharmaceuticals", "intravitreal and intrastromal anti-VEGF injections", "retinal diseases" including "macular degeneration" and "retinal neovascularization", "ranibizumab", and "bevacizumab", as well as relevant MeSH terms where applicable...Newer agents such as brolucizumab and faricimab offer prolonged durability and enhanced anatomic outcomes, while biosimilars provide cost-effective alternatives...Anti-VEGF therapies have revolutionized the field of ophthalmology, providing sight-saving treatment for a range of retinal diseases that were once considered untreatable or inevitably blinding. Today, anti-VEGF drugs are the go-to option for managing neovascular retinal disorders, thanks to their proven efficacy, favorable safety profile, and transformative impact on modern eye care."

Journal • Review • Age-related Macular Degeneration • Diabetic Macular Edema • Diabetic Retinopathy • Genetic Disorders • Glaucoma • Hematological Disorders • Inherited Retinal Dystrophy • Macular Degeneration • Ocular Inflammation • Oncology • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Retinitis Pigmentosa • Retinopathy of Prematurity • Uveitis • Wet Age-related Macular Degeneration • PRPH

Outcomes of and Surgical Technique for Treatment With High-Dose Aflibercept. (PubMed, J Vitreoretin Dis) - " A prospective pilot study was performed to analyze the short-term safety and visual gain (expressed in logMAR), including increase in intraocular pressure (IOP), resulting from a modified regimen consisting of 0.18 mL paracentesis followed by an intravitreal injection of 0.18 mL aflibercept (prefilled syringe), 0.20 mL aflibercept (vial), or 0.22 mL ziv-aflibercept (compounded). In 2 eyes (6.3%), reflux as a tiny bleb was noted. When high-dose aflibercept is neither available nor affordable, a patient's readily accessible and cost-effective regimen of aflibercept will allow an exact delivery of high-dose aflibercept, combining minimal drug reflux, minimal immediate increase in IOP, and potential clinical efficacy in the short term."

Journal • Age-related Macular Degeneration • Hematological Disorders • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Tuberculosis-related multifocal choroiditis (SOE 2025) - "An intraocular Ziv-Aflibercept injection was administered in the right eye in order to treat the recurrent intraocular hemorrhage... The main pathology of multifocal choroiditis is the inflammation of the choriocapillaris and the retinal pigment epithelium. The lesions affect the periphery as well as the posterior pole. The diagnosis depends on the appropriate clinical history and evidence of tuberculous infection (Mantoux or Quantiferon test, chest imaging)."

Macular Edema • Ocular Inflammation • Ophthalmology

12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept. (PubMed, Indian J Ophthalmol) - "Ziv-aflibercept demonstrated effectiveness in maintaining treatment outcomes in nAMD eyes previously treated with aflibercept. The treatment was well-tolerated with no reported adverse events. Ziv-aflibercept may be a cost-effective alternative and a potential solution to the financial burden associated with conventional anti-VEGF agents."

Journal • Retrospective data • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Aflibercept or ranibizumab for diabetic macular edema. (PubMed, Med Hypothesis Discov Innov Ophthalmol) - "Ranibizumab and aflibercept were equally effective in achieving the desired anatomical and functional results in patients with treatment-naïve DME in short-term follow-up without significant differences in injection counts between both drugs. Larger prospective, randomized, double-blinded trials with longer follow-up periods are needed to confirm our preliminary results."

Clinical • Journal • Diabetes • Diabetic Macular Edema • Diabetic Retinopathy • Macular Edema • Metabolic Disorders • Ophthalmology • Retinal Disorders • Type 2 Diabetes Mellitus

A combination of suprachoroidal injection of triamcinolone using a custom-made needle and intravitreal Ziv-aflibercept every eight weeks to manage naïve/denovo central DME: a single-center retrospective case series. (PubMed, Int J Retina Vitreous) - "Suprachoroidal injection of triamcinolone using a custom-made needle with the intravitreal agent Ziv-aflibercept to treat de novo/naïve central DME has favorable outcomes and adequate safety results. Moreover, this study demonstrated the benefit of adapting the previous treatment combination for extending the interval between anti-VEGF treatments from 4 to 8 weeks, which could prevent further expenses, especially in low-income countries.However, large multicenter randomized clinical trials with longer follow-up periods are needed to assess this treatment route, especially in low-income and resourced countries."

Clinical • Journal • Retrospective data • Cataract • Diabetic Macular Edema • Ophthalmology

Comparison of antiangiogenic agents (ranibizumab, aflibercept, bevacizumab and ziv-aflibercept) in the therapeutic response to the exudative form of age-related macular degeneration according to the treat-and-extend protocol- true head-to-head study. (PubMed, Int J Retina Vitreous) - "Results indicate that over 2 years, Intravitreal aflibercept on T&E provided better visual and anatomical improvements when compared to other drugs used in this study with significantly fewer injections."

Head-to-Head • Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Comparison of Efficacy and Safety of Mitomycin and Aflibercept Used to Support Primary Trabeculectomy. (clinicaltrials.gov) - P1 | N=64 | Completed | Sponsor: Medical University of Lublin | Unknown status ➔ Completed

Surgery • Trial completion • Glaucoma • Ophthalmology

Intravitreal Ziv-Aflibercept versus Bevacizumab for Naïve Central Retinal Vein Occlusion with Macular Edema: An Interim Analysis of a Randomized Non-Inferiority Trial. (PubMed, Clin Ophthalmol) - "The results also showed that IVZ was non-inferior to IVB for anatomical improvement but inconclusive for visual improvement. (identifier: TCTR20191205008)."

Head-to-Head • Journal • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes. (PubMed, J Ophthalmic Vis Res) - "However, IVZ had no significant effect on SCT. Baseline SCT and its monthly changes had no association with visual and anatomical outcomes."

Journal • Diabetic Macular Edema • Ophthalmology

Effectiveness of the Use of Three-Dose Intravitreal Ziv-Aflibercept in the Management of Diabetic Macular Edema in a Real-Life Setting. (PubMed, Clin Ophthalmol) - "No systemic or ocular adverse events occurred. The use of three consecutive monthly doses of intravitreal Ziv-aflibercept in a real-life setting is effective and safe in the management of diabetic macular edema."

Journal • Diabetes • Diabetic Macular Edema • Macular Edema • Metabolic Disorders • Ophthalmology

The use of aflibercept (VEGF trap) in mitigating sulfur mustard-induced corneal neovascularization in a rabbit model. (PubMed, Toxicol Rep) - "This study aimed to evaluate the efficacy of ziv-aflibercept and aflibercept in preventing and ameliorating corneal neovascularization (NV), respectively, following chemical eye exposure to SM vapor in a rabbit model...A single subconjunctival aflibercept treatment in an ocular formulation was administered 4 weeks after SM vapor exposure and subsequent to an initial 1-week treatment with 0.1 % dexamethasone...The substantial decrease in existing corneal NV in this group was confirmed by histology. These results reveal the powerful anti-angiogenic efficacy of the VEGF-trap for ameliorating existing NV as opposed to preventing NV development, revealing the ability of this treatment to mitigate corneal NV."

Journal • Preclinical • Inflammation • VEGFA

"در صورت مصرف دارو با نام تجاری zaltrap آزمایشات CBCW/diff پیش از شروع درمان و سپس در انتهای هر. سیکل درمانی انجام شود، فشار خون بیمار حداقل هر ۲ هفته توسط پزشک چک شود. کرونا هنوز تموم نشده و احتماد دارد دوباره همه گیر شود @merck #dizziness" (@sait11859965)

Quantitative assessment of silicone oil release with siliconized and silicone oil-free syringes by microflow imaging microscopy. (PubMed, Arq Bras Oftalmol) - "Flicking syringes to eliminate air bubbles results in increased numbers of particles released during intravitreal injections into the human vitreous."

Journal

Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection. (PubMed, BMC Ophthalmol) - P1/2 | "Ziv-aflibercept is a highly effective and safe drug in cases of DME resistant to previous ranibizumab injections especially in low-income countries."

Journal • Diabetes • Diabetic Macular Edema • Metabolic Disorders • Ophthalmology

Use of ziv-aflibercept in diabetic macular edema in a Ghanaian population. (PubMed, Eye (Lond)) - "IVZ (1.25 mg) was associated with significant improvement in BCVA and reduction in CMT at 6 and 12 months in eyes with DME. A randomized clinical trial is warranted to assess this potentially cost-effective intervention for DME in low-resource settings."

Clinical • Journal • Diabetic Macular Edema • Hypertension • Ophthalmology

Comparison of ziv-aflibercept and bevacizumab for treatment of naïve central retinal vein occlusion with macular edema: interim analysis of a randomized non-inferiority trial (ARVO 2022) - "Interim results demonstrated that ziv-aflibercept had comparable visual and anatomical outcomes with bevacizumab for treatment of CRVO with ME at 6-months of follow-up. Ziv-aflibercept was safe and efficacious; therefore enrollment to 42 patients should be continued."

Clinical • Head-to-Head • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

One year outcomes of eyes with polypoidal choroidal vasculopathy with ≥20/40 visual acuity treated with anti-vascular endothelial growth factor agents. (PubMed, Saudi J Ophthalmol) - "PRN anti-VEGF monotherapy in real-life situations for the treatment of naïve PCV eyes with good visual acuity (≥20/40) achieves maintenance or improvement of visual acuity through 12 months follow-up."

Journal • Age-related Macular Degeneration

Regression in polypoidal choroidal vasculopathy treated with ziv-aflibercept monotherapy - short term study. (PubMed, Saudi J Ophthalmol) - "IVZ leads to significant morphological changes on ICGA and OCT in terms of polyp regression and reduction of PED height, respectively, with a limited change in visual acuity. IVZ may serve as a cost-effective alternative to treat eyes with PCV."

Journal • Monotherapy • Age-related Macular Degeneration

The sterility, stability and efficacy of repackaged ziv-aflibercept for intravitreal administration. (PubMed, Sci Rep) - "However, the concentration of ziv-aflibercept decreased less than the minimum expected concentration of 8 ng/mL after 60 days at 4 °C and after 30 days at 25.8 °C. The repackaged anti-VEGF drug ziv-aflibercept does not lose stability or efficacy and remains uncontaminated if prepared under sterile conditions and stored at 4 °C for up to 60 days or stored at 25.8 °C for up to 30 days."

Journal

Fundus autofluorescence in the evaluation of diabetic macular edema treatment response. (PubMed, Gac Med Mex) - "In DME, composite indices with baseline FAF predict variables such as BCVA in the follow-up of patients receiving ziv-AFL."

Journal • Diabetic Macular Edema • Ophthalmology

Preoperative Bevacizumab and Ziv-Aflibercept Administration in PDR Subjects Undergoing PPV (clinicaltrials.gov) - P=N/A; N=568; Completed; Sponsor: Panhandle Eye Group, LLP; Recruiting ➔ Completed; N=300 ➔ 568

Clinical • Enrollment change • Trial completion • Diabetic Retinopathy • Retinal Disorders

PPV With Internal Limiting Membrane Peeling for Treatment-Naïve DME (clinicaltrials.gov) - P3; N=11; Completed; Sponsor: Rush Eye Associates; Recruiting ➔ Completed; N=250 ➔ 11; Trial completion date: Sep 2022 ➔ May 2021; Trial primary completion date: Sep 2022 ➔ May 2021

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Diabetic Macular Edema • Diabetic Retinopathy • Macular Edema • Ophthalmology • Retinal Disorders

Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization. (PubMed, Expert Opin Drug Saf) - "We provide a critical review of the safety of all the anti-VEGF agents currently used for treating myopic CNV including ranibizumab, aflibercept, conbercept, bevacizumab and ziv-aflibercept. Nonetheless, ocular adverse events following anti-VEGF therapy for myopic CNV may develop and these include worsening or new development of myopic traction maculopathy, increased risk of retinal detachment and progression of chorioretinal atrophy. Clinicians should be aware of these potential complications and evaluate them before and after anti-VEGF therapy."

Adverse events • Clinical • Journal • Review • Macular Degeneration • Ophthalmology • Retinal Disorders